The Dow Jones Industrial Average (^DJI) was up 46.85 (0.10%) points today, reaching 46,993.26, as the market balanced a complex narrative of central bank policy and escalating geopolitical risks. The primary driver for today's session is the Federal Open Market Committee (FOMC) meeting, with investors closely monitoring Chair Jerome Powell’s afternoon press conference. While the Federal Reserve is widely expected to maintain interest rates, market participants are searching for clues regarding the impact of ...

Market Performance - U.S. equity markets rebounded on March 17, 2026, with the S&P 500 rising 0.6% to 6,741.72, the Dow Jones increasing by 217.44 points (approximately 0.5%) to 47,163.85, and the Nasdaq Composite gaining 0.7% to close at 22,526.29 [1] - Positive sentiment was driven by optimism that geopolitical tensions in the Persian Gulf would not lead to long-term stagflation, despite elevated crude oil prices around $93.38 per barrel [2] Sector Performance - The financial and technology sectors were the main growth drivers, with Goldman Sachs gaining 2.57%, IBM rising 2.29%, and American Express increasing by 2.01% [3] - In technology, Nvidia's stock rose after reaffirming its forecast of $1 trillion in AI chip revenue by 2027, while Qualcomm jumped 3% following a dividend hike and a $20 billion share buyback announcement [4] Defensive Sector Trends - Defensive sectors faced pressure, with Johnson & Johnson falling 0.96%, and Amgen and Coca-Cola also declining as investors shifted towards growth-oriented assets [5] Travel Sector Developments - Delta Air Lines shares surged 6.6% after raising its revenue forecast for Q1 2026, citing increased demand from business and leisure travelers, which helped offset higher jet fuel costs [6] - This positive outlook led to a sector-wide rally, boosting American Airlines by 3.5%, United Airlines by 3.2%, and Southwest Airlines by 2.2% [6] Upcoming Market Events - Investors are focused on the Federal Reserve's policy decision on March 18, with expectations of interest rates remaining steady at 3.75% [7] - A wave of economic data, including housing starts and industrial production figures, is anticipated later in the week to provide insights into U.S. consumer health amid energy price volatility [8] After-Hours Earnings Highlights - Major companies like Walmart are under scrutiny for retail health, while tech firms such as Arista Networks and cloud-computing companies are expected to release updates that may impact market sentiment [9]

Core Viewpoint - Johnson & Johnson has demonstrated strong performance in the healthcare sector, with a notable increase in share price over the past year and year-to-date [1] Summary by Category Company Performance - Johnson & Johnson's shares have increased by 48% over the past 12 months [1] - The company has seen a 16% rise in share price year-to-date [1]

Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs top healthcare stocks. On March 10, Johnson & Johnson (NYSE:JNJ) announced the submission of a Type II variation application to the European Medicines Agency. The company is seeking approval of TECVAYLI (teclistamab) as a potential treatment for relapsed and refractory multiple Myeloma. Johnson & Johnson (JNJ) Targets Opportunities around Multiple Myeloma with TECVAYLI The company hopes to make TECVAYLI available at a time when patients with multiple m ...

Key Takeaways J&J's phase I NMIBC study of Erda-iDRS met its primary safety endpoint and showed encouraging activity.JNJ reported an 89% CR rate in intermediate-risk NMIBC with a median response duration of 18 months.JNJ's MoonRISe program is testing Erda-iDRS in phase II and III studies across multiple NMIBC settings.Johnson & Johnson (JNJ) reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with inte ...

Monte Rosa Therapeutics (GLUE) advanced in premarket trading on Monday as the company entered into a supply agreement with Johnson & Johnson (JNJ) to evaluate its MRT-2359 in combination with apalutamide for treating metastatic castration-resistant prostate cancer ...

Group 1: Investment Potential - Johnson & Johnson (NYSE: JNJ) is highlighted as a highly profitable blue chip stock, with Citi raising its price target from $250 to $274 while maintaining a Buy rating [1] - Citi's research note indicates that despite recent market volatility, the fundamentals of the medical technology sector remain "healthy" [1] - Citi's top picks in the sector include iRhythm and Medtronic, suggesting a competitive landscape [1] Group 2: Product Development and Regulatory Approvals - Johnson & Johnson announced the submission of a Type II variation application to the European Medicines Agency (EMA) for TECVAYLI® to treat adult patients with relapsed/refractory multiple myeloma [2] - The submission is supported by data from the Phase 3 MajesTEC-9 trial, which evaluates teclistamab's safety and efficacy against standard care in 614 patients [3] Group 3: Company Overview - Johnson & Johnson operates through two segments: Innovative Medicine and MedTech, focusing on various therapeutic areas including oncology, infectious diseases, and cardiovascular diseases [4] - The MedTech segment encompasses a wide range of medical devices used in cardiovascular intervention, orthopedics, and surgery [4]

Core Viewpoint - The article discusses the 12 most profitable blue-chip stocks to invest in currently, emphasizing the importance of diversification and identifying opportunities amidst market volatility [1][2][3]. Market Trends and Investment Strategy - Stephen Parker from JPMorgan Private Bank highlights that geopolitical events, such as the Iran war, can cause short-term market disruptions, particularly in energy markets, but typically do not have long-lasting effects [1][2]. - He advises clients to maintain a diversified and disciplined investment approach, seek opportunities during volatility, and start building a shopping list for potential investments [2][3]. Stock Selection Methodology - The selection of the 12 blue-chip stocks was based on stock screeners and holdings of blue-chip ETFs, focusing on those with the highest trailing twelve months (TTM) net income and net income margins [5]. - The list prioritizes stocks with the highest number of hedge fund holders as of Q3 2025, utilizing data from Insider Monkey's database [5][6]. Company Highlights - **AstraZeneca PLC (NASDAQ:AZN)**: - Price target raised to 16,000 GBp from 15,500 GBp by Guggenheim, maintaining a Buy rating after positive fiscal 2025 results [8]. - The FDA has accepted a supplemental Biologics License Application for Enhertu, with a Priority Review status for treating HER2-positive breast cancer [9][10]. - AstraZeneca focuses on developing and commercializing prescription medicines, including novel immuno-oncology treatments [11]. - **Johnson & Johnson (NYSE:JNJ)**: - Citi increased the price target to $274 from $250 while maintaining a Buy rating, citing healthy sector fundamentals despite recent volatility [12]. - The company submitted a Type II variation application to the EMA for TECVAYLI® to treat relapsed/refractory multiple myeloma [13][14]. - Johnson & Johnson operates in healthcare, with segments in Innovative Medicine and MedTech, covering various therapeutic areas and medical devices [15].

Core Viewpoint - The Court has granted preliminary approval for a $65 million settlement in an antitrust class action against Actelion Pharmaceuticals, now part of Johnson & Johnson, for allegedly preventing generic drug manufacturers from developing a cheaper version of its drug Tracleer [1] Group 1: Lawsuit Details - The lawsuit was initiated by the Government Employees Health Association (GEHA), which claimed that Actelion obstructed generic manufacturers from obtaining necessary samples of Tracleer, thereby hindering the market entry of generic alternatives [2] - GEHA alleged that Actelion not only refused to sell samples but also contractually prevented competitors from acquiring samples from pharmacies, effectively blocking all avenues for generic manufacturers [2] - The alleged actions resulted in no generic product being available for nearly four years after the Tracleer patent expired, leading to over $100 million in overpayments by GEHA and other Third-Party Payors for the drug [2] Group 2: Settlement and Impact - The settlement amount of $65 million represents nearly 50% of the conservative single damages estimate, providing significant relief to the class of entities that purchased Tracleer [3] - If finalized, the settlement will resolve over seven years of litigation and deliver compensation to those affected by the alleged antitrust practices [3] Group 3: Drug Information - Tracleer, the brand name for bosentan, is used to treat pulmonary artery hypertension (PAH), a chronic and potentially fatal condition affecting 10,000 to 20,000 people in the U.S., primarily women [4] - At the time of the alleged antitrust scheme, Actelion charged $75,000 per patient annually for Tracleer [4] Group 4: Legal Proceedings - The lawsuit was originally filed in 2018 but was dismissed in 2019 due to statute of limitations issues; however, the Fourth Circuit revived the case in 2021, allowing it to proceed [5] - The district court granted class certification for GEHA in September 2024, denying Actelion's motion for summary judgment, which set the stage for the trial [5]

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate- risk non-muscle-invasive bladder cancer Accessibility Statement Skip Navigation- Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer- Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profileRARITAN, N.J., March 13, 2026 /PRNewswire/ -- Johnson & ...